| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 04/12/2001 | WO2001025410A2 DIAGNOSTIC PROBES AND THERAPEUTICS TARGETING uPA AND uPAR |
| 04/12/2001 | WO2001025399A2 Non-invasive tumor imaging by tumor-targeted bacteria |
| 04/12/2001 | WO2001024834A1 Methods of preparing micro encapsulated agents for use in detection of tumors by ct imaging |
| 04/12/2001 | WO2001024833A2 In vivo assay for testing the phenotypic stability |
| 04/12/2001 | WO2001024831A2 Polymer stabilized neuropeptides |
| 04/12/2001 | WO2001024814A1 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 04/12/2001 | WO2001024705A1 Improved methods for delivering bioactive agents |
| 04/12/2001 | WO2001024696A1 Fullerene contrast agent for magnetic resonance imaging and spectroscopy |
| 04/12/2001 | CA2406882A1 Diagnostic probes and therapeutics targeting upa and upar |
| 04/12/2001 | CA2386806A1 Non-invasive tumor imaging by tumor-targeted bacteria |
| 04/12/2001 | CA2386228A1 Stabilized liquid pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi) polypeptides |
| 04/12/2001 | CA2386214A1 Fullerene contrast agent for magnetic resonance imaging and spectroscopy |
| 04/11/2001 | EP1090250A1 Hyperpolarized gas transport device and associated transport method |
| 04/11/2001 | EP1090249A2 Resilient containers for hyperpolarized gases |
| 04/11/2001 | EP1090032A2 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| 04/11/2001 | EP1089766A2 Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| 04/11/2001 | EP1089765A2 $i(IN VIVO) DETERMINATION OF METABOLIC FUNCTION FOR USE IN THERAPY MANAGEMENT |
| 04/11/2001 | EP1089662A1 Improvements in or relating to cardiac imaging |
| 04/11/2001 | CN1064355C Microcyclic chelants their chelates and uses thereof in the diagnostic field |
| 04/10/2001 | US6214798 Polypeptides |
| 04/10/2001 | US6214388 Immunoliposomes that optimize internalization into target cells |
| 04/10/2001 | US6214317 Diagnostic method for diabetes using C-13 labeled pyruvic acid |
| 04/10/2001 | US6214315 Radioactive embolizing compositions |
| 04/10/2001 | US6214253 Omega-hydrofluoroalkyl ethers, precursor carboxylic acids and derivatives thereof, and their preparation and application |
| 04/10/2001 | CA2070647C Use of an anticoagulant as a diagnostic agent |
| 04/05/2001 | WO2001023005A1 Antibody dye conjugates for binding to target structures of angiogenesis in order to intraoperatively depict tumor peripheries |
| 04/05/2001 | WO1996040281B1 Gas emulsions stabilized with fluorinated ethers having low ostwald coefficients |
| 04/05/2001 | DE10046508A1 Magnetic nanoparticles carrying specific binding agent reactive with intracellular molecule, useful for separating cells, particularly cancerous, and biomolecules |
| 04/05/2001 | CA2385593A1 Antibody-dye conjugates for angiogenesis target structures for intraoperative tumor edge visualization |
| 04/04/2001 | EP1088559A2 Galenic formulations |
| 04/04/2001 | EP1088558A2 Galenic formulations |
| 04/04/2001 | EP1088315A1 Nucleation and growth of magnetic metal oxide nanoparticles and its use |
| 04/04/2001 | EP1088062A1 Transplants for myocardial scars |
| 04/04/2001 | EP1087974A1 Carotene analog of porhyrins, chlorins and bacteriochlorins as therapeutic and diagnostic agents |
| 04/04/2001 | EP1087794A2 Utilization of 5-aminolevulinic acid or a derivative thereof for photodynamic diagnosis or photodynamic therapy of diseases of the parodontium and teeth |
| 04/04/2001 | EP1087793A2 Material for differently modifying the optical properties of different cells |
| 04/04/2001 | EP1087753A1 Targeted liposomal drug delivery system |
| 04/04/2001 | EP1087752A2 Method for producing liposomal formulations of active agents |
| 04/04/2001 | CN1290179A Bipapcitide-based pharmaceutical compositions for imaging and treating thrombi |
| 04/03/2001 | US6211355 Reacting cobalamin compound with chelating compound to compound useful for in vivo imaging of organs and tumors |
| 04/03/2001 | US6210742 Emulsions are suited for preparation of food products, personal care products, pharmaceutical products and industrial products |
| 04/03/2001 | US6210682 Immunization against rotavirus infection or rotavirus disease by administering to a subject a peptide nsp4 114-135, a peptide nsp4 120-147, or a toxoid thereof are disclosed. |
| 04/03/2001 | US6210655 Site-specific 13C-enriched reagents for diagnostic medicine by magnetic resonance imaging |
| 03/29/2001 | WO2001021218A2 Method for determining viability of a myocardial segment |
| 03/29/2001 | WO2001020977A1 Novel animal model of alzheimer disease with amyloid plaques and mitochondrial dysfunctions |
| 03/29/2001 | WO2001002851A8 Method for screening targeting dds preparation |
| 03/29/2001 | WO2000077039A3 Glp-1 as a diagnostic test to determine beta-cell function |
| 03/29/2001 | CA2384865A1 Novel animal model of alzheimer disease with amyloid plaques and mitochondrial dysfunctions |
| 03/28/2001 | EP1085896A1 Conformationally constrained backbone cyclized somatostatin analogs |
| 03/28/2001 | CN1063630C Surface-modified anticancer nanopartiles |
| 03/27/2001 | US6207877 Transgenic coagulation factor XIII defective animal and its use for testing wound healing and bleeding |
| 03/27/2001 | US6207821 Long-wavelength electromagnetic radiation and photoprotective tumor localizing agents for diagnosis |
| 03/27/2001 | US6207453 A replication-defective adeno-associated virus vector containing exogenous dna bound to a dna which codes for a rep protein; gene therapy |
| 03/27/2001 | US6207136 Fluorescent imaging method of saccharide uptake activity of living tissue |
| 03/27/2001 | US6207135 Biodegradable wall material of the particles is made from a blend of liquid crystals block polymers of polylactones and polyoxyethylene glycol or polylactones; controlled retention time; contrast of blood flow, organs; nontoxic; antiallergens |
| 03/27/2001 | US6207134 Ultrafine lightly coated superparamagnetic particles for MRI |
| 03/27/2001 | US6207133 Anti-tumoral therapy agent containing a contrast agent |
| 03/27/2001 | CA2076540C Recombinant antibodies specific for tnf-.alpha. |
| 03/27/2001 | CA2035492C Liquid lavage/ventilation of the pulmonary system |
| 03/22/2001 | WO2001020331A1 Substrates and screening methods for transport proteins |
| 03/22/2001 | WO2001020019A2 Implantable glucose sensor |
| 03/22/2001 | WO2001019967A1 Human inflammatory breast carcinoma xenograft capable of lymphovascular invasion and methods for its use |
| 03/22/2001 | WO2001019838A1 Macrocyclic chelants for metallopharmaceuticals |
| 03/22/2001 | WO2001019409A2 Method of tumor imaging |
| 03/22/2001 | WO2001019405A2 Magnetic nanoparticles having biochemical activity, method for the production thereof and their use |
| 03/22/2001 | CA2384429A1 Magnetic nanoparticles having biochemical activity, method for the production thereof and their use |
| 03/22/2001 | CA2382057A1 Macrocyclic chelants for metallopharmaceuticals |
| 03/21/2001 | EP1084712A2 X-ray contrast agents |
| 03/21/2001 | EP1084145A2 Antibodies to the ed-b domain of fibronectin, conjugates containing them and use thereof for diagnosis and therapy of tumors and diseases associated with angiogenesis |
| 03/21/2001 | EP1083936A1 Diagnostic method and diagnostic means used in carrying out said method |
| 03/21/2001 | EP0716091B1 Tris(substituted phenyl)bismuth derivative |
| 03/21/2001 | EP0714402B9 Polymer modification |
| 03/21/2001 | CN1288469A Monoclonal antibody anti alpha; V-integrin and it use to inhibit & alpha; V & beta; 6-integrain attachment to fibronectine |
| 03/21/2001 | CN1288373A Prepn. of a lipid blend and a phospholipid suspension contg. the lipid blend, and contrast agents based on these |
| 03/21/2001 | CN1287861A Aerogenic capsule for digestive canel barium meal contrast examination |
| 03/21/2001 | CN1063438C Alkenyl-benzoyl guanidine derivant, prepn. method and use thereof |
| 03/20/2001 | US6205352 Sentinel node identification using non-isotope means |
| 03/20/2001 | US6205349 Differentiating normal living myocardial tissue, injured living myocardial tissue, and infarcted myocardial tissue in vivo using magnetic resonance imaging |
| 03/20/2001 | US6204389 Cyanine dyes and synthesis methods thereof |
| 03/20/2001 | US6204366 Specific binding agents |
| 03/20/2001 | US6204299 Foaming agents used to prepare closed cell polyurethane foams |
| 03/20/2001 | US6204047 Growth differentiation factor-10 |
| 03/20/2001 | US6204007 Antibodies against E-selectin |
| 03/20/2001 | US6203778 Particulate radiopaque contrast agent for diagnostic imaging and microvascular characterization |
| 03/20/2001 | US6203777 Method of contrast enhanced magnetic resonance imaging using carbohydrate particles |
| 03/20/2001 | US6202855 Process for the selection of particles of a preselected size from a particulate pharmaceutical product |
| 03/15/2001 | WO2001018169A2 Agents and compositions and methods for diagnostic and/or treating or preventing plaque forming diseases |
| 03/15/2001 | WO2001018013A1 Prodrugs for liver specific drug delivery |
| 03/15/2001 | WO2001018011A1 Calcium complex of phosphorus containing ethylenediamine derivatives |
| 03/15/2001 | WO2001017567A2 Improved container composition for diagnostic agents |
| 03/15/2001 | WO2001017566A2 L-selectin contrast agents |
| 03/15/2001 | WO2001017561A1 Fluorescent dye angiography and dye-enhanced photocoagulation |
| 03/15/2001 | WO2001017524A1 Methods for treating cell proliferative disorders including cancer |
| 03/15/2001 | WO2000016810A8 Near infrared fluorescent contrast agent and fluorescence imaging |
| 03/15/2001 | DE19944893A1 Calcium-Komplex von [[(4R)4-[(carboxy-.kappa.O)methyl]amino-. Calcium complex of [[(4R) -4 - [(carboxy-.kappa.O) methyl] amino-. kappa.N]-6,9-bis[(carboxy-.kappa.O)methyl] -1-[(4,4-diphenylcyclohexyl)9oxy]-1-hydroxy-2-oxa -6,9-diaza-1-phophaundecan-11-yl-säure-.kappa.N6, .kappa.N9,.kappa.O11]1-oxidato(6-)]-, hexahydrogen, dessen Salze, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Therapie und als Zusatzstoff in der Diagnostik sowie Verfahren zur Herstellung der Komplexe und Mittel #### kappa.N] -6,9-bis [(carboxy-.kappa.O) methyl] -1 - [(4,4-diphenylcyclohexyl) 9oxy] -1-hydroxy-2-oxa-6.9-diaza-1 -phophaundecan-11-yl-acid-.kappa.N6, .kappa.N9, .kappa.O11] 1-oxidato (6 -)] -, hexahydrogen, its salts, pharmaceutical agents containing these complexes, their use in therapy and as an additive in the diagnosis and methods for producing the complexes and agents #### |
| 03/15/2001 | DE10013849A1 L-Selectin-Kontrastmittel L-selectin contrast agent |
| 03/15/2001 | CA2349434A1 Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| 03/14/2001 | EP1082416A2 Poly(adp-ribose)polymerase gene |
| 03/14/2001 | EP1082143A2 Mr signal-emitting coatings |
| 03/13/2001 | US6201165 Drug screening by contacting isolated cardiomyocyte having calcineurin, calcium calmodulin dependent kinase iv or ii alpha, p38, or mkk6 transgene with compound; measuring physiological parameter; and comparing to control |